Post-earnings recap
Reported
Mon, Nov 7, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a larger-than-expected loss per share, which contributed to a 2.86% decline in stock price following the earnings announcement. The lack of revenue figures and guidance may leave investors uncertain about the company's immediate future. Management's cautious tone suggests they are aware of the challenges ahead but are committed to addressing them.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.50 | N/A | -61.29% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over current performance but highlighted their commitment to improving operations. They are focused on advancing their pipeline despite the setbacks.
Management acknowledged the challenges faced this quarter.
They emphasized ongoing efforts to improve operational efficiency.
Future plans include focusing on pipeline development.